The high cost and complex logistics of cell and gene therapies pose significant challenges for reimbursement, hindering patient access. https://ow.ly/sl1S50SIzJR Pooja Rana, MPH and Jennifer (Goldenberg) Klarer, M.Sc.Eng. of The Dedham Group write about how manufacturers must take strategic approaches to navigate these approaches. Click the link to the article in this post to learn more.
The Dedham Group
Business Consulting and Services
New York, NY 16,899 followers
Management and Strategic Consulting Services
About us
The Dedham Group is the premier US oncology & specialty therapeutics strategy consulting firm that combines deep clinical expertise in specialty disease areas, commercial & market access expertise and proprietary analytics to provide highly differentiated recommendations & strategic support to our clients in the pharmaceutical and biotech industry. Our work focuses on being highly data-driven and developing highly custom and integrated strategies in exciting areas of clinical innovation which span oncology, cell & gene therapy, immunology, neurology, rare diseases and precision medicine. We are deeply embedded with our clients which span senior leaders across sales & marketing, market access, distribution & patient services, pricing & contracting and channel strategy across marquee brands on the cutting edge of clinical innovation from many of the most admired companies. Our team is comprised of highly talented entrepreneurial, collaborative and creative leaders that are focused on insights development, storytelling and creating custom strategies & products for our strategic clients, maintaining the high quality & deep specialization expectations of a boutique firm. Our organization prides itself on being a merit-driven, team-based, high-performance culture where our people care greatly about their clients’ careers, the impact of their work and the overall well-being of their colleagues.
- Website
-
http://www.dedhamgroup.com
External link for The Dedham Group
- Industry
- Business Consulting and Services
- Company size
- 51-200 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 2010
- Specialties
- Consulting, Healthcare, and Research
Locations
-
Primary
1 Penn Plaza
Suite 2505
New York, NY 10119, US
Employees at The Dedham Group
Updates
-
Creating a successful portfolio optimization strategy requires a nuanced understanding of market dynamics, technological innovations, and regulatory environments, writes Michael Hamlin. Here’s how to get started: https://ow.ly/xAe150RIXAu. #PortfolioOptimization #MarketDynamics #RegulatoryEnvironment #InvestmentStrategy #TechnologicalInnovations
-
The specialty therapeutic access landscape is changing quickly. https://ow.ly/cIl350Rpup1 The Dedham Group's Rebecca Leemputte shares how manufacturers can ensure patient support programs serve their intended purpose: providing access to life-saving therapies. #TherapeuticAccess #AccessToMeds #PharmaSolutions #HealthcareAdvocacy
How Pharma Can Improve Access with Support Program Evolution - The Dedham Group
https://dedhamgroup.com
-
Please welcome our 2024 Summer University Hire Class! While we have had many new team members join us in 2024, we are incredibly excited to welcome our 19 university hires this week! Anthony Casablanca Nicholas Colaw Isabella (Ella) Flood Lara Hairapetian William Huang Raahim Khan Eunice Kim Hayley McMorrow, PhD Jonathan Mehrara Garnett Nelson Christian Park Yoni Perla Laya Sathyan Narvella Sefah Shruti Shakthivel Daniel K. Shi Vipasha Soni Julia Tenner Emily Warden
-
Few drugs have gripped the American public, like GLP-1 weight-loss medications. The strong sales of GLP-1 drugs raise questions about how insulin pricing crackdowns will affect pipeline strategies and how biopharma manufacturers will address supply issues to support diabetes patients. In a recent BioSpace BioSpace article, The Dedham Group’s Manuel Jurado provides commentary on the connection between the GLP-1 and the insulin market. Check out the full article: https://ow.ly/Uhfc50RRFhb #GLP1 #Insulin #Biopharma #PharmaceuticalCompanies
As Sales of Weight Loss Drugs Skyrocket, the Insulin Market Falters | BioSpace
biospace.com
-
Unlock the power of market access success with PULSE Analytics by The Dedham Group. https://ow.ly/YV4G50Su9aA Our robust dataset equips you to navigate market challenges with confidence. Learn how to proactively address emerging specialty market needs and optimize resource allocation for enhanced strategic planning. Connect with us today!
-
In the interview with Healthcare de Jure (Healthcare NOW Radio), The Dedham Group’s James Pisano delves into challenges in behavioral health coverage and treatment delivery and how changes in healthcare parity legislation, benefit design, and innovative models either reshape the behavioral health environment or fall short. He also discusses how understanding these barriers helps define commercial strategy and product launch planning. Check out the full podcast episode: https://ow.ly/WmlM50R4M6f. #Healthcare #HealthcareLegislation #HealthcareIndustry #BehavioralHealth #TreatmentDelivery
Healthcare de Jure: James Pisano, Partner at The Dedham Group
soundcloud.com
-
In our latest thought leadership article, Michael Hamlin covers the keys to successful portfolio optimization and how pharma companies can attain the right balance to achieve their business objectives. Read it now: https://ow.ly/4LPO50RIXqX. #PharmaOptimization #PortfolioBalance #BusinessObjectives #PharmaInsights #HealthcareStrategy #PharmaLeadership #HealthcareInnovation #ThoughtLeadership
The Portfolio Optimization Balancing Act: Keys to Improving Business Outcomes - The Dedham Group
-
Few drugs have gripped the American public, like GLP-1 weight-loss medications. The strong sales of GLP-1 drugs raise questions about how insulin pricing crackdowns will affect pipeline strategies and how biopharma manufacturers will address supply issues to support diabetes patients. In a recent BioSpace BioSpace article, The Dedham Group’s Manuel Jurado provides commentary on the connection between the GLP-1 and the insulin market. Check out the full article: https://ow.ly/fM0k50RRFa6 #GLP1 #Insulin #Biopharma #PharmaceuticalCompanies
As Sales of Weight Loss Drugs Skyrocket, the Insulin Market Falters | BioSpace
biospace.com
-
Data presented at this year’s ASCO conference reinforced the importance of patient identification. Dedham Partners Matthew Cunningham and Aaron McKeon-Fish provided an overview of the conference and the Merck Moderna readouts for PharmaLive. Check out their insights here: https://ow.ly/oZsk50SileP
ASCO 2024 commentary: data and therapeutic standouts - PharmaLive
https://www.pharmalive.com